SymBio Pharmaceuticals - Termination of coverage
Edison Investment Research is terminating coverage on Brooge Energy (BROG), Tyman (TYMN), SymBio Pharmaceuticals (4582), Aspire Global (0EAZ),...
7 Views
SymBio Pharmaceuticals - The first whole quarter of internal SymBio sales
SymBio reported Q121 sales of ¥1.42bn of its drug Treakisym (bendamustine) for hematologic malignancies. This is the first quarter in which the...
555 Views
SymBio Pharmaceuticals - Treakisym RTD approved
SymBio announced on 23 September 2020 that it has received approval from the PMDA for the ready-to-dilute (RTD) formulation of Treakisym...
207 Views
SymBio Pharmaceuticals - At the turning point
SymBio is approaching a major transition as it prepares to begin internal marketing of its lead product Treakisym (bendamustine), launch new liquid...
99 Views
SymBio Pharmaceuticals - Top-line data from registrational DLBCL study
SymBio will be presenting data at the European Society of Hematology (EHA) meeting from its pivotal study in Japan of Treakisym (bendamustine) in...
95 Views